Who are Tygacil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CHLORTETRACYCLINE HYDROCHLORIDE, inhaled tobramycin, Minocycline HCl, Gentamicin - three days, Usual doses of tigecycline, Neomycin Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tigecycline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Tygacil — Competitive Intelligence Brief

Tygacil (TIGECYCLINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline-class Antibacterial [EPC]. Area: Infectious Disease.

marketed Tetracycline-class Antibacterial [EPC] 30S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tygacil (TIGECYCLINE) — Fresenius Kabi. Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tygacil TARGET	TIGECYCLINE	Fresenius Kabi	marketed	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
CHLORTETRACYCLINE HYDROCHLORIDE	CHLORTETRACYCLINE HYDROCHLORIDE		marketed	Tetracycline	30S ribosomal subunit	1950-01-01
inhaled tobramycin	inhaled tobramycin	Seattle Children's Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline HCl	Minocycline HCl	OraPharma	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Gentamicin - three days	Gentamicin - three days	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Usual doses of tigecycline	Usual doses of tigecycline	Air Force Specialized Hospital, Cairo, Egypt	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-24 — Tygacil · 8975242 · US
2029-02-05 — Tygacil · 7879828 · US
2030-10-08 — Tygacil · 8372995 · US
2033-04-07 — Tygacil · 9855335 · US

Sponsor landscape (Tetracycline-class Antibacterial [EPC] class)

Paratek Pharms · 2 drugs in this class
Fresenius Kabi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tygacil — Competitive Intelligence Brief. https://druglandscape.com/ci/tigecycline. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab